化合物WYC209 T5341

Product Introduction
Bioactivity


英文名: WYC-209

描述: WYC-209 是一种合成类视黄醇，是维甲酸受体激动剂。它主要通过 caspase 3途径抑制恶性鼠黑色素瘤肿瘤再生细胞的增殖，IC50值为 0.19 μM。

细胞实验: Cell proliferation rate was measured by using MTT colorimetric assay. Cells were seeded in 3D soft fibrin gel in 96-well microplates at a density to maintain control (untreated) cells in an exponential phase of growth during the entire experiment. Cells were incubated with various concentrations of compounds for each time point followed by incubation with 50?μL MTT reagent for 3?h at 37?°C. After incubation, 150?μL MTT solvent was added and absorbance was measured at 570?nm. All experiments were repeated at least three times. The percentage of viable cells was calculated and averaged for each well: percent growth?=?(OD-treated cells/OD control cells)?×?100, cell proliferation at each time point is normalized to base line cell survival at the time of initial compound treatment (day 0).

动物实验: Four- to six-week-old female and male C57BL/6 mice were used in mice experiment. Mice were randomized into different groups. In metastasis experiment, B16-F1 cell spheroids were selected from 3D 90-Pa fibrin gels and pipetted to single cells. These TRCs were harvested and the cell number was counted under microscopy. The cells were then suspended in PBS with appropriate cell density. Thirty thousand TRCs were intravenously injected into the tail vein of each wild-type C57BL/6 mouse. Five days later, inoculated mice were intravenous implanted with 0.022?mg/kg WYC-209, 0.22?mg/kg WYC-209, or 0.1% DMSO every two days. The mice were euthanized and examined for lung tumor formation at day 30. In treated TRCs injected in vivo experiments, B16-F1 cells were seeded into 3D 90-Pa fibrin gels and treated with 10?μM WYC-209 or 0.1% DMSO on day 3, then isolated treated TRCs colonies on day 5 and pipetted into single cell. 30,000 of TRCs were intravenously injected into the tail vein of each wild-type C57BL/6 mouse. No blinding was performed in the mice experiments.

体外活性: WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs), with an IC50 of 0.19?μM in a dose-dependent manner. WYC-209 also inhibits proliferation of TRCs of human melanoma, lung cancer, ovarian cancer, and breast cancer in culture.

体内活性: WYC-209 abrogates 87.5% of lung metastases of melanoma TRCs in immune-competent wild-type C57BL/6 mice at 0.22?mg?kg-1 without showing apparent toxicity.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 80 mg/mL (217.13 mM)
H2O : Insoluble


关键字: Apoptosis | WYC 209 | Retinoid X receptors | Inhibitor | Retinoic acid receptors | WYC-209 | Autophagy | RAR/RXR | inhibit

相关产品: Eriocalyxin B | SB 202190 | EPI-001 | (5Z,2E)-CU-3 | AEE788 | Anti-inflammatory agent 45 | Prosapogenin A | GSK2606414 | ZLDI-8 | Lonicerin

相关库: Anti-Cancer Compound Library | Nuclear Receptor Compound Library | Anti-Cancer Active Compound Library | Lipid Metabolism Compound Library | Apoptosis Compound Library | Metabolism Compound Library | Autophagy Compound Library | Reprogramming Compound Library | NO PAINS Compound Library | Covalent Inhibitor Library

化合物WYC209 T5341信息由TargetMol中国为您提供，如您想了解更多关于化合物WYC209 T5341报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途